designed a novel third-generation TanCAR targeting both FOLR1 and MSLN, combined with IL-12 secretion, to reduce the likelihood of tumor antigen escape and enhance CAR-T cell infiltration and antitumor activity. Here, FOLR1 is linked to neoplasm.